Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors

Archive ouverte

Holstein, M. | Mesa-Nunez, C. | Miskey, C. | Almarza, E. | Poletti, V. | Schmeer, M. | Grueso, E. | Ordonez Flores, J. C. | Kobelt, D. | Walther, W. | Aneja, M. K. | Geiger, J. | Bonig, H. B. | Izsvak, Z. | Schleef, M. | Rudolph, C. | Mavilio, F. | Bueren, J. A. | Guenechea, G. | Ivics, Z.

Edité par CCSD ; Cell Press -

International audience. The Sleeping Beauty (SB) transposon system is a non-viral gene delivery platform that combines simplicity, inexpensive manufacture, and favorable safety features in the context of human applications. However, efficient correction of hematopoietic stem and progenitor cells (HSPCs) with non-viral vector systems, including SB, demands further refinement of gene delivery techniques. We set out to improve SB gene transfer into hard-to-transfect human CD34(+) cells by vectorizing the SB system components in the form of minicircles that are devoid of plasmid backbone sequences and are, therefore, significantly reduced in size. As compared to conventional plasmids, delivery of the SB transposon system as minicircle DNA is approximately 20 times more efficient, and it is associated with up to a 50% reduction in cellular toxicity in human CD34(+) cells. Moreover, providing the SB transposase in the form of synthetic mRNA enabled us to further increase the efficacy and biosafety of stable gene delivery into hematopoietic progenitors ex vivo. Genome-wide insertion site profiling revealed a close-to-random distribution of SB transposon integrants, which is characteristically different from gammaretroviral and lentiviral integrations in HSPCs. Transplantation of gene-marked CD34(+) cells in immunodeficient mice resulted in long-term engraftment and hematopoietic reconstitution, which was most efficient when the SB transposase was supplied as mRNA and nucleofected cells were maintained for 4-8 days in culture before transplantation. Collectively, implementation of minicircle and mRNA technologies allowed us to further refine the SB transposon system in the context of HSPC gene delivery to ultimately meet clinical demands of an efficient and safe non-viral gene therapy protocol.

Consulter en ligne

Suggestions

Du même auteur

Genomic analysis of sleeping beauty transposon integration in human somatic cells

Archive ouverte | Turchiano, G. | CCSD

International audience. The Sleeping Beauty (SB) transposon is a non-viral integrating vector system with proven efficacy for gene transfer and functional genomics. However, integration efficiency is negatively affe...

Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs

Archive ouverte | Molina-Estevez, F. J. | CCSD

International audience. Fanconi anemia is a DNA repair-deficiency syndrome mainly characterized by cancer predisposition and bone marrow failure. Trying to restore the hematopoietic function in these patients, lenti...

Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34(+) cells from Fanconi anemia patients

Archive ouverte | Rio, P. | CCSD

International audience. Previous Fanconi anemia (FA) gene therapy studies have failed to demonstrate engraftment of gene-corrected hematopoietic stem and progenitor cells (HSPCs) from FA patients, either after autol...

Chargement des enrichissements...